SCHEDULE: Viking Global Investors Reports 4.2% Stake in Trevi Therapeutics
Beneficial Ownership Report (Schedule 13G)
Viking Global Investors LP and its affiliates have filed an amended Schedule 13G, disclosing a 4.2% beneficial ownership stake in Trevi Therapeutics, Inc. as of September 30, 2025.
Summary
- Viking Global Investors LP, along with several affiliated entities and individuals (O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet), collectively reported beneficial ownership of 5,128,875 shares of Trevi Therapeutics, Inc. common stock.
- This aggregate ownership represents 4.2% of Trevi Therapeutics' common stock outstanding.
- The percentage is based on 121,776,855 shares of common stock outstanding as of July 31, 2025, as reported in Trevi Therapeutics' Form 10-Q filed on August 7, 2025.
- The shares are held through various Viking Global entities, including Viking Global Opportunities Illiquid Investments Sub-Master LP (VGOP) with 3,436,346 shares (2.8%) and Viking Global Opportunities Drawdown (Aggregator) LP (VGOD) with 1,692,529 shares (1.4%).
- All reporting persons have shared voting and dispositive power over their respective beneficially owned shares, with no sole voting or dispositive power reported.
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently suggest positive or negative sentiment regarding the issuer's performance or prospects. It is a neutral, compliance-driven report.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of institutional ownership, common in the investment management industry. It indicates that Viking Global Investors, a prominent investment firm, maintains a significant, albeit passive, stake in Trevi Therapeutics, a biotechnology company. Such filings provide transparency into major shareholder positions but do not typically reflect operational or strategic shifts within the issuer's industry.
Related Party Transactions
- Viking Global Investors LP provides managerial services to Viking Global Opportunities Illiquid Investments Sub-Master LP (VGOP) and Viking Global Opportunities Drawdown (Aggregator) LP (VGOD).
- O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities Parent, have shared authority to dispose of and vote the shares beneficially owned by VGI and Opportunities Parent.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming Viking Global's continued passive investment in Trevi Therapeutics.
- Management: Awareness of a large, passive institutional holder, which may influence long-term strategic considerations but not day-to-day operations given the passive nature of the filing.
Key Dates
| Date | Description |
|---|---|
| 2025-07-31 | Date as of which 121,776,855 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2025-08-07 | Date Trevi Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC. |
| 2025-09-30 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-11-14 | Date the Schedule 13G Amendment No. 5 and the Joint Filing Agreement were executed and filed. |
Keywords
Viking Global Investors, Trevi Therapeutics, Beneficial Ownership, Schedule 13G, Institutional Ownership, Common Stock, Investment Management, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.